Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Nurix Therapeutics, Inc., Arcus Biosciences or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Nurix Therapeutics, Inc., Arcus Biosciences and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Nurix Therapeutics, Inc., Arcus Biosciences and Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Latest Biotechnology and Nurix Therapeutics, Inc., Arcus Biosciences, Inc. Stock News

As of July 31, 2026, Nurix Therapeutics, Inc. had a $2.4 billion market capitalization, compared to the Biotechnology median of $252.6 million. Nurix Therapeutics, Inc.’s stock is up 22.4% in 2026, down 0.7% in the previous five trading days and up 95.29% in the past year.

Currently, Nurix Therapeutics, Inc. does not have a price-earnings ratio. Nurix Therapeutics, Inc.’s trailing 12-month revenue is $36.8 million with a -928.4% net profit margin. Year-over-year quarterly sales growth most recently was -79.6%. Analysts expect adjusted earnings to reach $1.787 per share for the current fiscal year. Nurix Therapeutics, Inc. does not currently pay a dividend.

As of July 31, 2026, Arcus Biosciences, Inc. had a $3.5 billion market cap, putting it in the 62nd percentile of all stocks. Arcus Biosciences, Inc.’s stock is up 18.3% in 2026, down 0.8% in the previous five trading days and up 198.94% in the past year.

Currently, Arcus Biosciences, Inc. does not have a price-earnings ratio. Arcus Biosciences, Inc.’s trailing 12-month revenue is $236.0 million with a -156.4% net profit margin. Year-over-year quarterly sales growth most recently was -39.3%. Analysts expect adjusted earnings to reach $-3.483 per share for the current fiscal year. Arcus Biosciences, Inc. does not currently pay a dividend.

How We Compare Nurix Therapeutics, Inc., Arcus Biosciences and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Nurix Therapeutics, Inc., Arcus Biosciences and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Nurix Therapeutics, Inc., Arcus Biosciences and Inc. Growth Grades

Company	Ticker	Growth
Nurix Therapeutics, Inc.	NRIX	F
Arcus Biosciences, Inc.	RCUS	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Nurix Therapeutics, Inc. has a Growth Score of 18, which is Very Weak. Arcus Biosciences, Inc. has a Growth Score of 12, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Nurix Therapeutics, Inc., Arcus Biosciences or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Nurix Therapeutics, Inc., Arcus Biosciences or Inc. is the better investment when it comes to sustainable growth.

Nurix Therapeutics, Inc., Arcus Biosciences and Inc.’s Quality Grades

Company	Ticker	Quality
Nurix Therapeutics, Inc.	NRIX	F
Arcus Biosciences, Inc.	RCUS	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Nurix Therapeutics, Inc. has a Quality Score of 11, which is Very Weak. Arcus Biosciences, Inc. has a Quality Score of 6, which is Very Weak.

The Quality Stock Winner: No Clear Winner

Neither Nurix Therapeutics, Inc., Arcus Biosciences or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Nurix Therapeutics, Inc., Arcus Biosciences or Inc. is the better investment when it comes to quality.

Nurix Therapeutics, Inc., Arcus Biosciences and Inc.’s Momentum Grades

Company	Ticker	Momentum
Nurix Therapeutics, Inc.	NRIX	A
Arcus Biosciences, Inc.	RCUS	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Nurix Therapeutics, Inc. has a Momentum Score of 92, which is Very Strong. Arcus Biosciences, Inc. has a Momentum Score of 95, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Nurix Therapeutics, Inc., Arcus Biosciences and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Other Nurix Therapeutics, Inc., Arcus Biosciences and Inc. Grades

In addition to Growth, Quality and Momentum, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Nurix Therapeutics, Inc., Arcus Biosciences and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Nurix Therapeutics, Inc., Arcus Biosciences or Inc. Stock?

Overall, Nurix Therapeutics, Inc. stock has a Growth Score of 18, Momentum Score of 92 and Quality Score of 11.

Arcus Biosciences, Inc. stock has a Growth Score of 12, Momentum Score of 95 and Quality Score of 6.

Comparing Nurix Therapeutics, Inc., Arcus Biosciences and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.